Rameda targets raising export revenue share to 20% in 5 years
Updated 8/15/2024 7:16:00 AM
Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) is planning to increase its export revenue share to 20% within the next five years, up from the current 12%, Managing Director Amr Morsy told Asharq Business.
The company is exploring new markets in Latin America and registering products in Kuwait, with the aim of expanding beyond its current presence in Egypt, the Middle East, and Africa, Morsy noted.
He added that Rameda produces 70 pharmaceutical products and plans to introduce 47 more in the coming four years, with an annual investment of up to EGP 100 million.
Recently, Rameda received approval from the Egyptian Drug Authority (EDA) for price increases on all its major products.
This approval affects 22 stock-keeping units (SKUs) across key brands such as Colona, Augram, Recoxibright, Pentatrox, Protofix, Omnevora, Optaminess, Rametax, and Megafen, with average price increases ranging from 40% to 50%.
Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals.
It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.
Related News
